Bacillus Calmette-Guérin (BCG) Vaccine Adverse Events in Victoria, Australia: Analysis of Reports to an Enhanced Passive Surveillance System
Bacillus Calmette–Guérin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.
To describe the epidemiology of reported BCG AEFI in Victoria, Australia, particularly following the 2012 recall of Connaught BCG vaccine, substitution with Denmark-SSI vaccine and subsequent programme delivery adjustments.
Retrospective analysis of reported BCG AEFI in Victoria, Australia, for the 6-year period 2008–2013. Incidence rates were calculated using available doses-distributed, doses-administered and population data denominators with 95 % confidence intervals.
The predominant BCG AEFI reported were abscess and lymphadenopathy, with higher reports for males than for females (p = 0.039).The rates of AEFI per 10,000 doses distributed were similar for the Connaught and Denmark-SSI strains, at 11.6 and 15.4, respectively (p = 0.414). When doses administered rather than doses distributed were considered, the rate of reported Denmark-SSI AEFI was much higher, at 62.8 per 10,000 doses administered. Meaningful result interpretation was hampered by a lack of a BCG vaccination register, multiple disparate providers and absent doses-administered data prior to the recall.
Effective AEFI surveillance is of paramount importance as countries are faced with unplanned vaccine strain changes following the 2012 BCG recall and subsequent global vaccine supply shortages. The Australian experience and lessons learned serve as a timely reminder to BCG vaccination programmes worldwide to review AEFI surveillance systems.
KeywordsVaccine Strain Adverse Event Follow Immunization Passive Surveillance System Drug Administration Error Adverse Event Follow Immunization Report
This study would not be possible without the valued contribution of the SAEFVIC nurses and paediatricians, who respond to AEFI reports and provide clinical review of cases. We thank the parents for permission to use the photograph in Fig. 2 and Kana Volin for BCG doses-distributed data.
Funding and conflicts of interest
No sources of funding were used in the preparation of this study. Hazel J. Clothier, Laine Hosking, Nigel W. Crawford, Melissa Russell, Mee Lee Easton, Julie-Ann Quinn and Jim P. Buttery have no conflicts of interest that are directly relevant to the content of this study. Hazel Clothier is a recipient of an Australian Postgraduate Award.
- 1.World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol Rec. 2004;79(4):27–38.Google Scholar
- 2.Barry C, Waring J, Stapledon R, Konstantinos A, National Tuberculosis Advisory Committee CDNA. Tuberculosis notifications in Australia, 2008 and 2009. Commun Dis Intell Q Rep. 2012;36(1):82–94.Google Scholar
- 3.World Health Organization. Information sheet: observed rate of vaccine reactions bacille Calmette–Guerin (BCG) vaccine. Geneva: World Health Organization; 2012.Google Scholar
- 5.National Health and Medical Research Council. The Australian immunisation handbook. 9th ed. Australia: Australian Government, Department of Health and Aging; 2008. p. 297–302.Google Scholar
- 6.National Tuberculosis Advisory Committee. The BCG vaccine: information and recommendations for use in Australia. Commun Dis Intell Q Rep. 2006;30:109–15.Google Scholar
- 7.The BCG vaccine: information and recommendations for use in Australia. National Tuberculosis Advisory Committee update October 2012. Commun Dis Intell Q Rep. 2013;37(1):E65–72.Google Scholar
- 8.World Health Organization. Global tuberculosis report. 2013. http://www.who.int/tb/publications/global_report/en/. Accessed 1 June 2014.
- 9.Fitzgerald MJ, Duclos P. The reporting and management of adverse reactions to bacillus Calmette–Guerin (BCG) vaccination. Can Dis Wkly Rep (Rapport hebdomadaire des maladies au Canada). 1991;17(19):98–100.Google Scholar
- 17.Department of Health and Ageing. Tuberculosis (BCG) vaccine: urgent medicine recall. 2012. http://www.tga.gov.au/safety/recalls-medicine-tuberculosis-bcg-vaccine-120620.htm. Accessed 29 Sept 2013.
- 18.Department of Health and Ageing. Tuberculosis bacillus Calmette–Guerin (BCG) vaccine recall fact sheet. Health alerts. 2012. http://www.health.gov.au/internet/main/publishing.nsf/Content/bcg-factsheet.htm. Accessed 26 Oct 2013.
- 19.Department of Health Victoria. Bacille Calmette–Geurin (BCG) vaccine for tuberculosis: frequently asked questions. In: Department of Health, editor. Information for health professionals. Melbourne: Victoria; 2012.Google Scholar
- 21.Lotte A, Wasz-Hockert O, Poisson N, Dumitrescu N, Verron M, Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res (Fortschritte der Tuberkuloseforschung Progres de l’exploration de la tuberculose). 1984;21:107–93.Google Scholar
- 22.Australian Bureau of Statistics. Australian demographic statistics, June 2012, estimated resident population by single year of age, Victoria. 2012. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun2012?OpenDocument. Accessed 23 May 2014.
- 23.Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria. Commun Dis Intell. 2011;35(4):294–8.Google Scholar
- 24.Department of Health Victoria. Adverse events reporting. immunisation. 2012. http://www.health.vic.gov.au/immunisation/saefvic.htm.
- 26.Clothier HJ, Selvaraj G, McMinn A, Lewis G, Crawford NW, Buttery JP. SAEFVIC: surveillance of adverse events following immunisation (AEFI) in Victoria, 2012 Vic Infect Dis Bull. 2013;16(4) (in press).Google Scholar
- 27.Al Awaidy S, Bawikar S, Prakash KR, Al Rawahi B, Mohammed AJ. Surveillance of adverse events following immunization: 10 years’ experience in Oman. East Mediterr Health J. 2010;16(5):474–80.Google Scholar
- 32.Linehan MF, Nurmatov U, Frank TL, Niven RM, Baxter DN, Sheikh A. Does BCG vaccination protect against childhood asthma? Final results from the Manchester Community Asthma Study retrospective cohort study and updated systematic review and meta-analysis. J Allergy Clin Immunol. 2014;133(3):688–95 e14.Google Scholar